Table 4.
CD134+ | CD137+ | GITR+ | CD3+ CD8+ CD25+ | CD95+ | HLA-DR+ | CD69+ | ||
---|---|---|---|---|---|---|---|---|
Media | TD | 8 (5.8–14.0) | 5.7 (3.2–9.9) | 9.2 (6.2–15.4) | 6.6 (3.9–9.3) | 28.6 (15.8–43.4) | 12.6 (8.0–25.6) | 18.1 (12.3–28.8) |
ASD | 9.8 (7.2–16.7) | 7.4 (3.3–14.6) | 7.1+ (5.1–11.5) | 3.7 (1.9–8.9) | 27.4 24.8–39.8) | 14.4 (12.2–18.5) | 16.5 (12.7–25.3) | |
PHA | TD | 14.9 (9.2–21.5) | 36.6 (31.6–47.3) | 20.9 (12.8–38.0) | 58.1 (43.3–69.0) | 35.3 (21.1–50.68) | 25.5 (13.7–38.0) | 65.5 (55.7–75.1) |
ASD | 10.3* (8.5–13.9) | 45.6* (39.9–52.7) | 23.7 (16.0–40.4) | 40.1* (22.0–52.26) | 36.1 (23.7–43.3) | 25 (18.5–39.5) | 69.3 (56.4–74.3) |
Data are presented as median and interquartile ranges.
p<0.05 unstimulated (media alone) levels in ASD children compared with unstimulated levels in typically developing controls.
p<0.05 stimulated responses in ASD children compared with stimulated responses in typically developing controls.